Purpose: to evaluate differences in echocardiographic parameters between patients with preclinical diastolic dysfunction (PDD) and heart failure with preserved ejection fraction (HFpEF) and to identify predictors of transition from PDD to HFpEF.
Material And Methods: Echocardiographic parameters were recorded in 325 patients with PDD and 50 healthy subjects. PDD and HFpEF were diagnosed by tissue Doppler imaging of the left ventricle (LV) during exercise stress test and detection of symptoms of heart failure.
Results: There were significant differences between both groups of patients and control group as well as between groups of patients with PDD and HFpEF in LV mass index, maximal left atrial (LA) volume index, systolic blood pressure, LV and LA parameters of longitudinal strain and strain rate. Patients with PDD and subsequent development of HFpEF had high values of LA stiffness and interatrial mechanical dyssynchrony. These parameters were independent predictors of HFpEF development in patients with PDD.
Conclusion: Predictors of HFpEF identified in this study provide an opportunity for early detection of patients with PDD with high risk of HFpEF development.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: The amplitude of resting-state electroencephalographic (rsEEG) rhythms is a promising neurophysiological biomarker to investigate the abnormalities of oscillatory neurophysiological thalamocortical mechanisms related to the general cortical arousal and vigilance in wakefulness in patients with dementia due to neurodegenerative diseases as Alzheimer's disease (ADD), Parkinson's disease (PDD) and Lewy Body disease (DLB). Here, we tested the hypothesis that the reactivity of posterior rsEEG alpha (about 8-12 Hz) rhythms during the transition from eyes-closed to -open condition may be lower in PDD patients than in DLB patients.
Methods: A Eurasian database provided clinical-demographic-rsEEG datasets in 35 ADD patients, 65 PDD patients, 30 DLB patients, and 25 matched cognitively unimpaired (Healthy) persons.
Biomarkers.
Alzheimers Dement
December 2024
Qingdao Municipal hospital, Qingdao university, Qingdao, Shandong, China.
Background: Neurofilament light chain protein (NfL) in cerebrospinal fluid (CSF) reflects the severity of neurodegeneration, with its altered concentrations discovered in Parkinson's disease (PD) and Parkinson's disease dementia (PD-D).
Method: A total of 259 people were recruited in this study, including 85 healthy controls (HC) and 174 neonatal PD patients from the Parkinson's Progression Markers Initiative (PPMI). Multiple linear regression and linear mixed effects models were used to examine the associations of baseline/ longitudinal CSF NfL with cognitive decline and other CSF biomarkers.
Biomarkers.
Alzheimers Dement
December 2024
The First Affiliated Hospital, Sun Yat-sen Univesrity, Guangzhou, Guangdong, China.
Background: The objectives of the study is to assess the clinical utility of the MemTrax Memory Test for detection of cognitive impairment in patients with PD.
Method: The MemTrax and Montreal Cognitive Assessment (MoCA) were administered to 61 healthy controls (HC), 102 PD patients with normal cognition (PD-N), 74 PD patients with mild cognitive impairment (PD-MCI) and 52 PD patients with dementia (PD-D). The MemTrax performance, MTx-%C, MTx-RT and MTx-Cp, and the MoCA scores were comparatively analyzed.
Biomarkers.
Alzheimers Dement
December 2024
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.
Background: Co-morbid Alzheimer's disease (AD) pathology is a major risk factor for cognitive impairment (CI) in PD, but whether and how AD co-pathology affects the clinical phenotype of PD-CI is incompletely understood. Recently validated plasma biomarkers for AD pathology, such as ptau217, hold great promise to revolutionize the diagnosis of neurodegenerative diseases. Here, we used plasma ptau217 to detect AD co-pathology in a well-characterized cohort of PD patients with CI and examine its associations with APOE4 genotype, cognitive profile, and cerebral hypometabolism on FDG-PET.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
The Feinstein Institutes for Medical Research, Manhasset, NY, USA.
Background: The Parkinson's disease (PD) cognition-related covariance pattern (PDCP) was derived from network analysis of metabolic positron emission tomography (PET). The expression score is a feasible imaging biomarker that correlates with neuropsychological test performance. Graph analysis within specific networks characterizes brain function, particularly in terms of assortativity, which reflects the tendency to connect to nodes with similar degree values.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!